BRAINTREE, Mass., Nov. 20, 2019 /PRNewswire/ -- Haemonetics
Corporation (NYSE: HAE), a global medical technology company
focused on delivering innovative hematology solutions to drive
better patient outcomes, announced global commercial
availability for the four-channel TEG® 6s PlateletMapping® ADP
& AA assay cartridge. Intended for use with the TEG 6s
Hemostasis Analyzer System, the cartridge is FDA cleared in the
U.S. for use in cardiology and cardiovascular surgery and is
CE-marked and available internationally with broader
indications.
The PlateletMapping ADP & AA cartridge is used by clinicians
to assess a patient's bleeding and thrombotic risk due to
inhibition of platelet function caused by anticoagulants such as
aspirin. By providing four channels of dried-in-place reagents
including HKH (Kaolin with Heparinase), ActF (Activator F), ADP
(adenosine-5'-diphosphate) and AA (Arachidonic Acid), the cartridge
can help clinicians measure a patient's ability to coagulate, or
form a blood clot.
"The release of the PlateletMapping ADP & AA cartridge marks
another milestone in our commitment to developing meaningful
technologies that help improve the efficiency and effectiveness of
care in critical areas of medicine," said Stew Strong, President,
Global Hospital at Haemonetics. "On the heels of our FDA clearance
for use of the TEG 6s analyzer in U.S. adult trauma settings, this
product release further strengthens our TEG portfolio, making it
the only cartridge-based hemostasis analyzer that allows a
clinician to assess both global hemostasis and platelet function at
the site of care."
"Platelet function can be affected by factors such as genetics,
antiplatelet therapy or surgical procedures," said Jan Hartmann, M.D., Vice President, Medical
Affairs at Haemonetics. "The PlateletMapping ADP & AA cartridge
provides clinicians with the timely and relevant results they need
to assess the patient's platelet function, and ways that it might
be impaired. This information can help them more confidently
determine a diagnosis and appropriate therapy."
The PlateletMapping ADP & AA cartridge is now available for
use with the TEG 6s system in a number of countries within
North America, Europe, Latin
America and Asia
Pacific.
About Haemonetics
Haemonetics (NYSE: HAE) is a global
healthcare company dedicated to providing a suite of innovative
hematology products and solutions for customers, to help them
improve patient care and reduce the cost of healthcare. Our
technology addresses important medical markets: blood and plasma
component collection, the surgical suite and hospital transfusion
services. To learn more about Haemonetics, visit
www.haemonetics.com.
Investor
Contact:
|
Media
Contact:
|
Olga Guyette,
Director-Investor Relations
|
Carla Burigatto,
VP-Communications
|
(781)
356-9763
|
(781)
348-7263
|
olga.guyette@haemonetics.com
|
carla.burigatto@haemonetics.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/haemonetics-releases-teg-6s-plateletmapping-adp--aa-assay-cartridge-globally-300961962.html
SOURCE Haemonetics Corporation